[go: up one dir, main page]

FI943805L - Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon - Google Patents

Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon Download PDF

Info

Publication number
FI943805L
FI943805L FI943805A FI943805A FI943805L FI 943805 L FI943805 L FI 943805L FI 943805 A FI943805 A FI 943805A FI 943805 A FI943805 A FI 943805A FI 943805 L FI943805 L FI 943805L
Authority
FI
Finland
Prior art keywords
treatment
multiple sclerosis
adenine derivatives
substituted adenine
substituted
Prior art date
Application number
FI943805A
Other languages
English (en)
Swedish (sv)
Other versions
FI943805A0 (fi
FI943805A7 (fi
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of FI943805A0 publication Critical patent/FI943805A0/fi
Publication of FI943805L publication Critical patent/FI943805L/fi
Publication of FI943805A7 publication Critical patent/FI943805A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI943805A 1992-02-19 1993-02-18 Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoito on FI943805A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (3)

Publication Number Publication Date
FI943805A0 FI943805A0 (fi) 1994-08-18
FI943805L true FI943805L (fi) 1994-10-19
FI943805A7 FI943805A7 (fi) 1994-10-19

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943805A FI943805A7 (fi) 1992-02-19 1993-02-18 Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoito on

Country Status (15)

Country Link
US (4) US5310732A (fi)
EP (1) EP0626853B1 (fi)
JP (1) JP2688113B2 (fi)
AT (1) ATE192045T1 (fi)
AU (1) AU682818B2 (fi)
BR (1) BR9305907A (fi)
CA (1) CA2130275C (fi)
CH (1) CH684310A5 (fi)
DE (1) DE69328474T2 (fi)
DK (1) DK0626853T3 (fi)
FI (1) FI943805A7 (fi)
HU (1) HU218656B (fi)
NO (2) NO309025B1 (fi)
RU (1) RU2130308C1 (fi)
WO (1) WO1993016706A1 (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
AU678557B2 (en) * 1992-05-19 1997-06-05 Scripps Research Institute, The Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
CA2191230C (en) * 1994-05-26 2001-02-27 Dennis A. Carson 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
JPH10512549A (ja) * 1994-12-22 1998-12-02 オーソ・フアーマシユーチカル・コーポレーシヨン 可溶性の２−クロロ−２’−デオキシアデノシン配合物
IL117090A (en) * 1995-02-10 2000-07-26 Schering Ag Pharmaceutical compositions containing oxazolidinone derivatives
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
NZ520852A (en) * 2000-02-18 2004-03-26 Southern Res Inst Intermediates and methods for synthesizing 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7301005B2 (en) 2000-11-01 2007-11-27 Salvatore Albani Immunomodulatory peptides derived from heat shock proteins and uses thereof
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
US20060135463A1 (en) * 2002-09-27 2006-06-22 Wood Christopher B Methods and compositions for the treatment of lupus using clofarabine
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
DE602004028448D1 (de) * 2003-03-28 2010-09-16 Ares Trading Sa Orale zubereitungen enthaltend cladribin
EA009714B1 (ru) * 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
EP2272503B1 (en) 2003-03-28 2013-03-20 Ares Trading S.A. Oral formulations of cladribine
KR20060041254A (ko) * 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
WO2005063246A1 (en) * 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
EP1835922B1 (en) * 2004-12-22 2009-05-20 Merck Serono SA Combination treatment for multiple sclerosis
EP2263678B1 (en) 2004-12-22 2014-06-11 Merck Serono SA Cladribine regimen for treating early secondary progressive Multiple Sclerosis
WO2006076641A2 (en) 2005-01-14 2006-07-20 Monosol Rx, Llc Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
EP2971287B1 (en) 2013-03-15 2019-08-14 GPB Scientific, LLC On-chip microfluidic processing of particles
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
AU2016311278B2 (en) * 2015-08-24 2021-03-25 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AU2018372007A1 (en) 2017-11-24 2020-07-09 Merck Patent Gmbh Cladribine regimen for use intreating progressive forms of multiple sclerosis
AU2021342333A1 (en) 2020-09-10 2023-04-06 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
CA3209648A1 (en) 2021-03-03 2022-09-09 Ursula BOSCHERT SHAFAATIAN Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572069C3 (de) * 1966-03-12 1976-01-08 Hoechst Ag, 6000 Frankfurt Lichtempfindliche Schicht zur Herstellung von Druckformen
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
EP0314011A3 (de) * 1987-10-30 1990-04-11 F. Hoffmann-La Roche Ag Purinderivate
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
HUT68030A (en) 1995-05-29
US5310732A (en) 1994-05-10
ATE192045T1 (de) 2000-05-15
CH684310A5 (de) 1994-08-31
RU94038043A (ru) 1996-11-20
CA2130275A1 (en) 1993-09-02
US5506214A (en) 1996-04-09
RU2130308C1 (ru) 1999-05-20
DE69328474D1 (de) 2000-05-31
NO942765D0 (no) 1994-07-25
HU218656B (hu) 2000-10-28
NO309025B1 (no) 2000-12-04
NO20000762D0 (no) 2000-02-16
DE69328474T2 (de) 2000-09-28
AU682818B2 (en) 1997-10-23
JP2688113B2 (ja) 1997-12-08
NO20000762L (no) 1994-09-13
FI943805A0 (fi) 1994-08-18
AU3724993A (en) 1993-09-13
CA2130275C (en) 1999-06-29
EP0626853B1 (en) 2000-04-26
BR9305907A (pt) 1997-10-21
DK0626853T3 (da) 2000-08-07
HU9402392D0 (en) 1994-10-28
US5506213A (en) 1996-04-09
NO322328B1 (no) 2006-09-18
EP0626853A1 (en) 1994-12-07
US5541164A (en) 1996-07-30
WO1993016706A1 (en) 1993-09-02
NO942765L (no) 1994-09-13
FI943805A7 (fi) 1994-10-19
JPH07507540A (ja) 1995-08-24

Similar Documents

Publication Publication Date Title
FI943805L (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
FI934369A0 (fi) Operatoerarbetsstation foersedd med stoedmontage foer monitor
FI945441A0 (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi
FI934424L (fi) Tid-frekvens -interpolering med tillaempning pao laoghastighets talkodning
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
ITMI931306A1 (it) Procedimento microbico per la preparazione di mevinolina
FI931740L (fi) Semisyntetiska glukosaminoglykaner innehaollande a-l-galakturonsyra somaer substituerad i 3-staellning med nukleofila radikaler
ITMI913465A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fuoroetano
NO930574L (no) Fremgangsmaate for fremstilling av desfluran
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
FI933487L (fi) Jaestvaerdstammor med defekter i N-glykosyleringen
KR930702990A (ko) 섬유성 질병 치료제로서의 프로스타사이클린- 및 카르바사이클린 유도체
KR950700739A (ko) β-카르볼린의 새로운 용도(New Use of β-Carbolines)
NO940190D0 (no) Anvendelse av x-ketoglutarat
FI931688L (fi) Benzoxazinon- och benzotiazinonderivat med effekt pao hjaertblodkaerlen
FI922716L (fi) Foerfarande i samband med framstaellning av plaststycken
ITMI922181A0 (it) Procedimento per la preparazione di perfluoro-2-metil-4-metossipentano
FI943660A7 (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi
KR890701106A (ko) 과지혈증의 치료를 위한 옥소퀴나졸린 유도체의 용도
FIU920062U0 (fi) Tillaegsanordning i samband med personlyftaren
LV5057A3 (lv) Hipoksantina atvasinajumu iegusanas panemiens
SE9200780D0 (sv) Composition for therapeutic use
ITTO920153A0 (it) Apparecchiatura per il trattamento laser di pezzi
UA285S (uk) Набір меблів для відпочинку

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: TMI REIDEKA